Richard Mason
CEO
Apollo Therapeutics
This biopharmaceutical company translates fundamental medical research into pre-clinical and clinical-stage therapies targeting oncology, major inflammatory disorders, and rare diseases. By developing a diverse portfolio of biological hypotheses, the company enhances treatment options and patient outcomes in medical centers.
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$405MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Richard Butt
Chief Scientific Officer
Product
Problem
The process of translating basic medical research breakthroughs into effective therapies for oncology, inflammatory disorders, and rare diseases is often slow and inefficient. Traditional pharmaceutical development models can be risk-averse, hindering the exploration of diverse biological hypotheses and potentially delaying the availability of novel treatments.
Solution
Apollo Therapeutics operates as a portfolio biopharmaceutical company, accelerating the development of innovative medicines by leveraging breakthroughs in biology and basic medical research. The company employs a scalable R&D platform, accessing discoveries from partnerships with leading universities and research institutes. Apollo develops a diversified portfolio of therapeutic programs with uncorrelated risk through internal discovery efforts and strategic in-licensing or acquisition of clinical-stage programs. This portfolio approach allows for data-driven decision-making and efficient capital allocation across a range of therapeutic areas, including oncology, immunology, and metabolic disease.
Target Audience
Apollo Therapeutics targets patients with unmet medical needs in oncology, major inflammatory disorders, and rare diseases, as well as pharmaceutical companies seeking to in-license or acquire promising therapeutic programs.
Features
- Access to breakthroughs in basic medical research from six partner universities and research institutes.
- A diversified portfolio of over 20 active therapeutic programs, with six currently in clinical development.
- Focus on first-in-class and/or best-in-class therapeutics in major commercial markets.
- Internal expertise in biology, small molecule, and monoclonal antibody discovery.
- Utilization of human genetics, including Mendelian randomization, to infer disease causality for molecular targets.
- A "hub-and-spoke" operational model with a centralized management team and dedicated program leaders for each therapeutic program.
- Clinical programs include a Phase 2 anti-IL18 mAb (Camoteskimab) for inflammatory indications and a Phase 2 anti-ZIP12 mAb (APL-9796) for pulmonary hypertension.
- Development of bispecific FGF21/GLP-1 dual receptor agonists and small molecule GCN2 and CK2α inhibitors.